Literature DB >> 15352897

Review article: systemic and topical steroids in inflammatory bowel disease.

J Schölmerich1.   

Abstract

Steroids are still widely used in the treatment of inflammatory bowel diseases. Pharmacological studies have shown that there is no major abnormality in the pharmacokinetics of steroids in these disorders. Foam preparations with rectal application decrease the bioavailability to low levels, eliminating systemic complications. For oral use, 'nonsystemic' steroids have been developed. In ulcerative colitis, steroids are rarely needed as 5-aminosalicylates are effective in the majority of patients. This is true for rectal application in distal colitis, as well as in more extensive disease. In Crohn's disease, steroids are more often used; however, in population-based studies, less than 50% of patients have been treated with steroids, as there are alternative treatments available for the large group of patients with mild to moderate activity. For those patients needing steroid treatment, budesonide seems to be a good choice in active disease, but has not shown convincing effects in the maintenance of remission over longer periods of time. There is no place for long-term steroid treatment in ulcerative colitis and very little in Crohn's disease--immunosuppression with azathioprine or related drugs is certainly the better alternative.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352897     DOI: 10.1111/j.1365-2036.2004.02059.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2018-01-09       Impact factor: 10.864

2.  Mechanism of glucocorticoid regulation of the intestinal tight junction barrier.

Authors:  Michel A Boivin; Dongmei Ye; John C Kennedy; Rana Al-Sadi; Chris Shepela; Thomas Y Ma
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-10-26       Impact factor: 4.052

3.  Increased feelings with increased body signals.

Authors:  Eduardo P M Vianna; Joel Weinstock; David Elliott; Robert Summers; Daniel Tranel
Journal:  Soc Cogn Affect Neurosci       Date:  2006-06       Impact factor: 3.436

4.  Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice.

Authors:  Rudolf Schicho; Martin Storr
Journal:  Pharmacology       Date:  2012-03-12       Impact factor: 2.547

Review 5.  Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab.

Authors:  Pamela R Puthoor; Edwin F de Zoeten
Journal:  Biol Ther       Date:  2013-01-04

6.  Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Xiaojing Zhao; Changcheng Zhou; Jingjing Ma; Yunjuan Zhu; Min Sun; Peixue Wang; Yi Zhang; Haiqin Ma; Hongjie Zhang
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

Review 7.  Optimizing drug therapy in inflammatory bowel disease.

Authors:  Arun Swaminath; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2007-12

8.  Solitary rectal ulcer syndrome: addition of rectal therapies to biofeedback is more effective than biofeedback alone.

Authors:  Saeed Abdi; Narjes Tavakolikia; Mehdi Yamini; Mohammad Bagheri; Amir Sadeghi; Mohamad Amin Pourhoseingholi; Shabnam Shahrokh; Morteza Aghajanpoor Pasha
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.